Exploring the potential of saruparib in overcoming venetoclax resistance in AML
Acute myeloid leukaemia (AML) is a highly aggressive type of blood cancer. In particular, elderly and medically unfit patients face a poor prognosis. Treatment with venetoclax and azacitidine improved the outcome for these patients, yet drug resistance remains a significant issue. Combining the poly (ADP-ribose) polymerase (PARP)1/2 inhibitor talazoparib with venetoclax and azacitidine was suggest
